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1. Introduction
Ketamine has been a subject of debate in recent years due 
to its illicit use in some parts of the world. However, in 
regions with limited resources, it is still a very valuable 
option. Ketamine was first publicized as a “battle field 
anesthetic” and it still preserves its unique place in 
pediatric anesthesia with features such as maintaining a 
state of dissociated consciousness along with spontaneous 
breathing, intact laryngeal reflexes, and hemodynamic 
stability (1). For anesthesiologists who are in the “battle 
field” of anesthetic management every day, ketamine 
provides a safety zone for sedated but spontaneously 
ventilated children, especially in remote conditions such as 
radiotherapy units where sedation is an essential practice 
to keep children calm and motionless (2). However, there 
has been disagreement about the ketamine doses needed 
for a continuous and steady level of sedation during 
repeated radiotherapy sessions in children. A tendency to 
tolerance occurrence to ketamine has been claimed when 
it is used in a repetitive manner and the opposite has also 
been reported (3–5). The current literature also suggests 
that N-methyl-D-aspartate (NMDA) receptor antagonists 
themselves have tolerance-preventive effects and may 
inhibit tolerance during long-term sedative and opioid 
administration (6,7). 
Any alteration in drug requirement to maintain 
therapeutic or targeted effects has always been an issue 
of interest for clinicians when repeat doses of any agent 
are used. In this paper, we report the analysis of ketamine 
doses needed and the recovery times in pediatric oncology 
patients undergoing repeated radiotherapy sessions. This 
paper may also add some more recent information for the 
use of ketamine where circumstances limit the anesthetic 
options.
2. Materials and methods
After approval from the Başkent University School of 
Medicine’s Ethics and Research Committee (KA09/247) 
and informed consent of the patients’ parents, 33 pediatric 
patients undergoing radiotherapy due to oncologic 
disorders were enrolled in this single-blind prospective 
study. Patients younger than 1 year and older than 14 years; 
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patients with cardiac, renal, or liver function abnormalities; 
those who were already under sedative drug treatment or 
allergic to the drugs to be used; and patients for whom the 
study drugs were contraindicated were excluded from the 
study.  
Pediatric patients who were fasted for 6 h were 
admitted to the preparation room, where they received 
2 mg/kg ketamine and 10 µg/kg atropine intravenously. 
All patients were monitored by electrocardiography, 
noninvasive blood pressure, and pulse oximeter and a 
closed-circuit camera system in the room. Sedation level 
was assessed by the Children’s Hospital of Wisconsin 
Sedation Scale and scores of 3 and 4 were accepted as 
adequate for the procedure to start radiotherapy (8). If the 
score exceeded 4, the rescue drug to be administered was 
ketamine at 0.5 mg/kg. After the procedure, the patients 
were observed until they achieved a score of 20 according 
to the Vancouver Sedative Recovery Scale and this stage 
was defined as “full recovery” to record the duration of 
“recovery time”. 
Patients’ demographic data (age, sex, weight), cancer 
type, ASA physical status, and duration and total number 
of radiotherapy sessions were noted. We included details 
about patients’ pain according to the nurses’ notes (as 
none, mild, moderate, or severe) in the files, since the 
age group of the patients was not even suitable for Wong-
Baker Faces Pain Scale. Total ketamine consumption to 
maintain the targeted sedation level during each session, 
additional dose administration, and recovery time were 
recorded. Adverse events such as apnea, laryngospasm, 
bronchospasm, desaturation (SpO2 < 93%), respiratory 
depression, bradycardia, sedation levels deeper or more 
superficial than intended, excessive salivation, allergy, 
nausea and vomiting, and need for emergency medication 
were also noted after each session. The study drugs were 
prepared, labeled, and administered by an anesthetist 
according to the study protocol and data were recorded by 
an anesthetist blind to the amount of the study drug used. 
2.1. Statistical analysis
Data analysis was performed using SPSS 11.0 (SPSS Inc., 
Chicago, IL, USA). Data of the continuous variables were 
presented as mean with standard deviation (SD) and 
minimum and maximum values. Categorical data were 
described in numbers or percentages as appropriate. The 
Friedman ANOVA test was used for analysis of repeated 
measures such as total ketamine consumption and recovery 
times. P < 0.05 was considered as statistically significant. 
3. Results
Data of 33 patients during 635 consecutive radiotherapy 
sessions were evaluated. For one patient, radiotherapy was 
stopped at the 5th session due to the critical condition of the 
Table. Demographic data of the patients and duration and total number of 
radiotherapy sessions (mean ± SD or n).
 (n = 32)
Age (years) 2.70 ± 0.84 
Weight (kg) 13.02 ± 2.51 
Sex (M/F) 19/13
ASA physical status (II/III) 31/1
Duration of radiotherapy sessions (min) 3.79 ± 1.77 
Total number of sessions 19.68 ± 8.37 
Cancer types of the patients (n)
Primary spinal glioma
Neuroblastoma
Atypical teratoid tumor
Leukemia
Rhabdomyosarcoma
Sacral bone tumor
Medulloblastoma
Neuroectodermal tumor
1
1
12
4
1
2
8
3
Pain levels according to nurse notes in the files (n)
None
Mild
Moderate 
Severe
0
4
16
12
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patient. This case was excluded from the data analysis due 
to paucity of the number of repeat sessions. The patients 
who required benzodiazepines due to hallucinations and 
restlessness were also excluded from the study so as not 
to intervene with the sole assessment of ketamine use. 
Demographic data of the patients included and duration, 
total number of radiotherapy sessions, cancer type, and 
pain assessment are presented in the Table. 
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Figure 1. Total ketamine consumption required to complete the consecutive radiotherapy sessions.
Figure 2. The recovery times after each consecutive radiotherapy session.
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Mean ketamine consumption at the first session 
and the last session was 25.8 ± 14.5 mg and 25.4 ± 10.3 
mg, respectively. There was no significant alteration in 
total ketamine consumption required to complete the 
radiotherapy periods during consecutive procedures (P > 
0.05) (Figure 1). However, the recovery times started to 
decrease by the fourth session (P = 0.02) and continued to 
decrease onwards during the whole study period (P = 0.001) 
(Figure 2). The mean of the first recovery time was 13.68 ± 
3.99 min, whereas the mean of the last recovery time was 
7.66 ± 6.35 min. The patients required additional ketamine 
administration 54 times in 47 of 635 sessions (7.4%).
One patient in one session experienced transient 
desaturation (SpO2: 90%), which was resolved with a 
jaw-thrust maneuver in less than 2 min (the approximate 
duration we approached the patient). He also had coughing 
and needed repositioning and aspiration of secretions. 
Another patient developed a mild allergic reaction with 
cutaneous manifestations to atropine.
4. Discussion
In this study, we evaluated ketamine doses needed and 
the recovery times during repeated radiotherapy sessions 
in pediatric oncology patients. There was no significant 
alteration in total ketamine consumption required to 
complete the radiotherapy periods during consecutive 
procedures; however, the recovery times started to 
decrease by the fourth session and continued to decrease 
onwards during the whole study period.
Efficient sedation with an absolute motionless state 
and intact airway is essential during radiotherapy sessions 
where the treated child and the anesthesia team have 
been isolated from each other. These requirements lead 
anesthetists to convey a sedation plan providing a similar 
sedated state and a recovery profile even after many 
numbers of repeated procedures such as radiotherapy 
sessions (9). However, repeat sessions may cause 
tolerance to the sedative agent used (10,11). Tolerance is 
a challenging situation that physicians often encounter 
during opioid use in clinical practice. The severity and 
duration of the stimulus as well as pharmacokinetic and 
pharmacodynamic alterations have been suspected for 
development of tolerance to the therapeutic action of 
drugs.
Ketamine has been a preferable anesthetic/analgesic 
drug with its predictable sedation and recovery features 
for diagnostic and therapeutic procedures in children 
outside the operating room, such as in radiotherapy 
units (12). Due to many receptor interactions, ketamine’s 
unique properties are not limited to sedation and 
analgesia; it is also efficient in maintaining the airway and 
stable hemodynamics along with antihyperalgesic and 
antiproinflammatory effects (1). Ketamine anesthesia has 
been reported to be related to increased radiosensitivity of 
tumors (13). This may also prove that ketamine would be 
more beneficial during radiotherapy. However, ketamine 
may also raise a concern for increased dose requirements 
or insufficient sedation levels and/or durations after 
repeat administrations, although ketamine itself has been 
suggested to play a tolerance-preventive role for opioids 
during sedation in pediatric intensive care units (1,11).  
Since there is no real pain experience or invasive 
stimulus during radiotherapy sessions, the main aim 
of ketamine-induced sedation is to preserve a steady 
“dissociated” state in children. In this study, sufficient 
sedation level and duration were achieved without a need 
for an increase in initial ketamine dose or additional 
drug administrations. The expected recovery time after 
2 mg/kg ketamine was more than 15 min (12), but in 
our study the recovery time decreased by approximately 
50% after repeat sessions at a rate higher than in previous 
reports (14). This may be interpreted as a decrease in the 
dissociation period of the thalamus and the limbic system, 
which basically enables the sedative effect of ketamine via 
NMDA receptors. Upregulated or desensitized NMDA 
receptors may hypothetically be responsible for the limited 
duration of desynchronization of the thalamus and limbic 
system after recurrent exposure to the drug. If there has 
been a strong stimulus, such as pain in burn patients 
who also undergo repeat ketamine-induced sedation 
sessions for dressing changes, tolerance occurrence may 
become more explicit by stimulation of miscellaneous 
receptors, which may cause a noticeable tolerance-like 
response in subjects (5,14). However, lack of an ongoing 
strong procedural stimulation during radiotherapy 
sessions lessens the anticipation for the upregulation of 
receptors. Thus, we may speculate that this tolerance-like 
effect depends more on a pharmacokinetic mechanism 
than a pharmacodynamic one. Besides, after repeated 
administrations, hepatic metabolism-based alterations in 
the pharmacokinetics of ketamine were shown to decrease 
circulating and brain levels of the drug and its active 
metabolites and increase inactive oxidation metabolites, 
thus resulting in a more rapid recovery (15).  
The first limitation of our study may be the ketamine 
dose regimen, which may be considered as a flaw in the 
methodology. Although this dose was not very small, our 
initial intention was to cover all procedures, even with 
planning sessions, which require more time. However, 
eventless procedural periods and acceptable recovery 
durations allowed us to continue with this dosing. 
Another reason to choose ketamine at a higher dose was 
that most of the patients already had painful tumors, 
which required some pain relief for positioning. Another 
limitation was the brief duration of the sessions to detect 
a need for dose increase to cover the therapy duration in 
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each consecutive session. Any need for increased doses 
could have been observed if the duration of the procedure 
was long enough for ketamine’s sedative effect to disappear 
during the intervention. However, we tried to prevent 
an unintentional and subjective tendency to change the 
amount of drug used for the procedure by using a sedation 
scale that clarifies the end-point for the level of sedation. 
Thus, this allowed us to optimize and standardize the 
amount of ketamine. In addition we tried to identify the 
recovery time according to a recovery scale to assess the 
time required for a similar recovery level in each child. 
In conclusion, a requirement for an incremental 
increase in ketamine dose after subsequent administrations 
was not detected, despite a significant decrease in recovery 
times being anticipated when ketamine is used repeatedly 
for sedative purposes in consecutive radiotherapy sessions. 
The cross-section of this procedural overview might be 
reproduced with further larger studies.
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